Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher

Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;: pubmed publisher

Cytlak U, Resteu A, Pagan S, Green K, Milne P, Maisuria S, et al. Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. Immunity. 2020;53:353-370.e8 pubmed publisher

Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019;35:238-255.e6 pubmed publisher

Mezzadra R, Sun C, Jae L, Gomez Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106-110 pubmed publisher

Patel S, Sanjana N, Kishton R, Eidizadeh A, Vodnala S, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537-542 pubmed publisher

Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher